
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
The update for EU annex 1 is more than a simple revision, solidifying the expectation that facility fully understand their processes and systems.






